Abstract 138P
Background
Systemic inflammatory markers (SIM) are closely related to the prognosis of various tumors. However, most of the studies were mainly limited to examining the preoperative level of these markers to evaluate prognosis. Reports on the significance of postoperative SIM in predicting the long-term prognosis of gastric cancer (GC) were rare. Therefore, this study aims to explore the preoperative and postoperative longitudinal changes of SIM in patients with GC and the impact on long-term prognosis.
Methods
The prospectively collected data from 2180 patients with GC who underwent radical gastrectomy between January 2009 and December 2014 at Fujian Medical University Union Hospital (FMUUH) were retrospectively analyzed. Changes in SIM between preoperatively and 1-6 months and 12 months postoperatively were reported. Cox univariate and multivariate analyses were performed to determine the prognosis of GC.
Results
In multivariate analysis, higher preoperative systemic inflammation score (pre-SIS) was independent predictor of poor prognosis (P <0.05). Further analysis showed that the area under the curve (AUC) of pre-SIS for prediction of 5-year overall survival (OS) was highest [0.605 (95% CI 0.584-0.6250)]. The optimal time of remeasurement was 12 months postoperatively, based on a longitudinal profile of SIS and accuracy in predicting 5-year OS [AUC: 0.712 (95% CI 0.630 - 0.785)]. According to the association between the conversion of SIS and OS, we classified patients into three risk groups. Kaplan-Meier (K-M) curves showed significant differences in OS among risk groups. Further Cox multivariate regression analysis showed that only risk groups of SIS and pTNM stage were independent prognostic factors for OS.
Conclusions
The efficacy of SIS in predicting prognosis 12 months after surgery is superior, and the elevation of SIS 12 months after surgery predicts poor prognosis. These findings provide support for the remeasurement of SIS 12 months after surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Prognostic influence of mean platelet volume on stage III rectal cancer patients: A tertiary cancer center study
Presenter: Pavan Jonnada
Session: e-Poster Display Session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session